Literature DB >> 16364720

Altered growth patterns of colorectal liver metastases after thermal ablation.

Mehrdad Nikfarjam1, Vigayaragavan Muralidharan, Christopher Christophi.   

Abstract

BACKGROUND: Thermal ablation by radiofrequency or laser is used increasingly for the treatment of colorectal liver metastases. Recurrence after thermal ablation is common and occurs both locally and at distant sites. One possible cause of this recurrence may be a result of growth stimulation of micrometastases in the remaining liver. This study examined the impact of thermal ablation on growth patterns of hepatic micrometastases.
METHODS: Colorectal liver metastases were induced in male CBA-strain mice via an intrasplenic injection of a murine-derived cancer cell line. Subtotal thermal ablation of the left posterior lobe of the liver (30% of total liver volume) was performed by neodymium yttrium-aluminum-garnet laser 7 days after induction of metastases. The distribution, number, cross-sectional diameter, volume, and proliferation rate of established neoplasms were compared with controls at 21 days after tumor induction. The effect of thermal ablation of 7% of the total liver volume by laser on the expression of vascular endothelial growth factor (VEGF), basic fibroblast growth factor 2 (FGF-2), transforming growth factor beta, and cellular proliferation (Ki-67 antigen) adjacent to the ablated site was assessed by immunohistochemistry in separate groups of animals at specific time points after therapy.
RESULTS: Thermal ablation did not alter the overall volume, number, size, and proliferation rate of neoplasms 21 days after laser ablation. There were no extrahepatic metastases after therapy. The number of neoplasms in the regenerated posterior lobe was equivalent to control despite subtotal ablation (29 +/- 2 vs 27 +/- 2; P = NS). A greater amount of metastases occupied the regenerated thermal-ablated lobe compared with controls (55% +/- 4% vs 29% +/- 3%; P < .04). Thermal ablation stimulated liver proliferation adjacent to the treatment site at 12 hours compared with untreated controls. Stimulation peaked at 72 hours (20% +/- 1% vs 1% +/- 1%; P < .001) and persisted to 21 days after therapy. FGF-2 and VEGF expression increased in liver tissue adjacent to the ablation site compared with baseline, peaking at 12 hours (112% +/- 2% vs 102% +/- 1%; P < .001) and 72 hours (114% +/- 2% vs 101% +/- 1%; P < .001), respectively.
CONCLUSIONS: Thermal ablation promotes the progression of micrometastases to form macroscopically detectable neoplasms in treated regenerating liver. This effect may relate to an increased expression of VEGF and FGF-2 adjacent to the treatment site.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16364720     DOI: 10.1016/j.surg.2005.07.030

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  23 in total

1.  Radiofrequency ablation-induced upregulation of hypoxia-inducible factor-1α can be suppressed with adjuvant bortezomib or liposomal chemotherapy.

Authors:  Marwan Moussa; S Nahum Goldberg; Gaurav Kumar; Rupa R Sawant; Tatyana Levchenko; Vladimir Torchilin; Muneeb Ahmed
Journal:  J Vasc Interv Radiol       Date:  2014-10-16       Impact factor: 3.464

2.  Insufficient radiofrequency ablation promotes the growth of non-small cell lung cancer cells through PI3K/Akt/HIF-1α signals.

Authors:  Jun Wan; Wei Wu; Yun Chen; Ningning Kang; Renquan Zhang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-02-27       Impact factor: 3.848

3.  Hepatic Thermal Ablation: Effect of Device and Heating Parameters on Local Tissue Reactions and Distant Tumor Growth.

Authors:  Erik Velez; S Nahum Goldberg; Gaurav Kumar; Yuanguo Wang; Svetlana Gourevitch; Jacob Sosna; Tyler Moon; Christopher L Brace; Muneeb Ahmed
Journal:  Radiology       Date:  2016-07-13       Impact factor: 11.105

4.  Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency Ablation.

Authors:  Gaurav Kumar; S Nahum Goldberg; Svetlana Gourevitch; Tatyana Levchenko; Vladimir Torchilin; Eithan Galun; Muneeb Ahmed
Journal:  Radiology       Date:  2017-09-06       Impact factor: 11.105

5.  Local tumor progression patterns after radiofrequency ablation of colorectal cancer liver metastases.

Authors:  Marc Napoleone; Ania Z Kielar; Rebecca Hibbert; Sameh Saif; Benjamin Y Kwan
Journal:  Diagn Interv Radiol       Date:  2016 Nov-Dec       Impact factor: 2.630

6.  Adjuvant Medications That Improve Survival after Locoregional Therapy.

Authors:  F Edward Boas; Etay Ziv; Hooman Yarmohammadi; Karen T Brown; Joseph P Erinjeri; Constantinos T Sofocleous; James J Harding; Stephen B Solomon
Journal:  J Vasc Interv Radiol       Date:  2017-05-17       Impact factor: 3.464

7.  Changes in growth factor levels after thermal ablation in a murine model of colorectal liver metastases.

Authors:  Theodora Fifis; Caterina Malcontenti-Wilson; Jason Amijoyo; Beatrice Anggono; Vijayaragavan Muralidharan; Mehrdad Nikfarjam; Christopher Christophi
Journal:  HPB (Oxford)       Date:  2011-03-02       Impact factor: 3.647

Review 8.  Postablation Immune Microenvironment: Synergy between Interventional Oncology and Immuno-oncology.

Authors:  DaeHee Kim; Joseph P Erinjeri
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

Review 9.  Is there a genetic signature for liver metastasis in colorectal cancer?

Authors:  Cristina Nadal; Joan Maurel; Pere Gascon
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

10.  New paradigm in the management of liver-only metastases from colorectal cancer.

Authors:  Matteo Donadon; Dario Ribero; Gareth Morris-Stiff; Eddie K Abdalla; Jean-Nicolas Vauthey
Journal:  Gastrointest Cancer Res       Date:  2007-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.